Biosyent a garp pick I find quite a bit of value in this company. Trailing twelve month earnings of around 4.8 million, return on equity over 18% and net cash balance of over 20 million. At today's prices you are paying very little for the growth prospects of this company however their pipeline has never been stronger. With Tibella coming to market I expect a strong second half of the year and 2021 has many catalysts going for it.